CN115515980A - C19 c38双特异性抗体 - Google Patents
C19 c38双特异性抗体 Download PDFInfo
- Publication number
- CN115515980A CN115515980A CN202180031216.2A CN202180031216A CN115515980A CN 115515980 A CN115515980 A CN 115515980A CN 202180031216 A CN202180031216 A CN 202180031216A CN 115515980 A CN115515980 A CN 115515980A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981990P | 2020-02-26 | 2020-02-26 | |
| US62/981,990 | 2020-02-26 | ||
| US202062990330P | 2020-03-16 | 2020-03-16 | |
| US62/990,330 | 2020-03-16 | ||
| US202063094838P | 2020-10-21 | 2020-10-21 | |
| US63/094,838 | 2020-10-21 | ||
| PCT/US2021/019685 WO2021173844A1 (en) | 2020-02-26 | 2021-02-25 | C19 c38 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115515980A true CN115515980A (zh) | 2022-12-23 |
Family
ID=75108863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180031216.2A Pending CN115515980A (zh) | 2020-02-26 | 2021-02-25 | C19 c38双特异性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11299551B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4110818A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7811176B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220159989A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515980A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021226582A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173257A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295896A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010549A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021173844A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173844A1 (en) | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
| CN118139638A (zh) * | 2021-08-25 | 2024-06-04 | 拜格拉夫55公司 | 靶向免疫抑制b细胞的抗体 |
| CN118139639A (zh) * | 2021-08-25 | 2024-06-04 | 拜格拉夫55公司 | 治疗与免疫抑制b细胞相关联的癌症的方法 |
| CN115850479B (zh) * | 2021-09-16 | 2025-08-12 | 盛禾(中国)生物制药有限公司 | 一种抗cd24抗体或其抗原结合片段及其应用 |
| CN114921497A (zh) * | 2022-05-17 | 2022-08-19 | 郑州大学第一附属医院 | 一种双靶向cd19/cd38嵌合抗原受体t细胞的制备方法和应用 |
| TW202440636A (zh) * | 2023-03-21 | 2024-10-16 | 美商傳記55有限公司 | Cd19/cd38多特異性抗體 |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
| WO2026064774A1 (en) * | 2024-09-23 | 2026-03-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies for immune checkpoint inhibitor combination therapies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007234621A1 (en) * | 2001-01-31 | 2007-12-13 | Biogen Idec Inc. | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| US20090076251A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2445530B1 (en) * | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
| HK1217023A1 (zh) | 2013-05-28 | 2016-12-16 | Numab Innovation Ag | 新型抗体 |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| WO2017011342A1 (en) | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| EP3481410A2 (en) | 2016-07-08 | 2019-05-15 | Paul C. Tumeh | Compositions and treatment methods for cancer immunotherapy |
| CA3032430A1 (en) | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| WO2019136311A2 (en) | 2018-01-05 | 2019-07-11 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| WO2019197979A1 (en) | 2018-04-10 | 2019-10-17 | Y-Biologics Inc. | Cell engaging binding molecules |
| US20220089752A1 (en) | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| EP4090369A4 (en) | 2020-01-15 | 2024-06-26 | The Board of Trustees of the Leland Stanford Junior University | PERICYTE-SPARKING THERAPY |
| WO2021173844A1 (en) * | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
| CN118139639A (zh) * | 2021-08-25 | 2024-06-04 | 拜格拉夫55公司 | 治疗与免疫抑制b细胞相关联的癌症的方法 |
| CN118139638A (zh) * | 2021-08-25 | 2024-06-04 | 拜格拉夫55公司 | 靶向免疫抑制b细胞的抗体 |
| TW202440636A (zh) * | 2023-03-21 | 2024-10-16 | 美商傳記55有限公司 | Cd19/cd38多特異性抗體 |
-
2021
- 2021-02-25 WO PCT/US2021/019685 patent/WO2021173844A1/en not_active Ceased
- 2021-02-25 AU AU2021226582A patent/AU2021226582A1/en active Pending
- 2021-02-25 KR KR1020227032841A patent/KR20220159989A/ko active Pending
- 2021-02-25 JP JP2022552176A patent/JP7811176B2/ja active Active
- 2021-02-25 CA CA3173257A patent/CA3173257A1/en active Pending
- 2021-02-25 IL IL295896A patent/IL295896A/en unknown
- 2021-02-25 EP EP21713268.7A patent/EP4110818A1/en active Pending
- 2021-02-25 CN CN202180031216.2A patent/CN115515980A/zh active Pending
- 2021-02-25 MX MX2022010549A patent/MX2022010549A/es unknown
- 2021-04-13 US US17/229,751 patent/US11299551B2/en active Active
-
2022
- 2022-03-02 US US17/685,206 patent/US12509527B2/en active Active
- 2022-03-02 US US17/685,201 patent/US12540194B2/en active Active
- 2022-03-02 US US17/685,216 patent/US20220185908A1/en not_active Abandoned
-
2025
- 2025-12-11 US US19/417,172 patent/US20260103536A1/en active Pending
-
2026
- 2026-01-22 JP JP2026009136A patent/JP2026086474A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007234621A1 (en) * | 2001-01-31 | 2007-12-13 | Biogen Idec Inc. | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| US20090076251A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
Non-Patent Citations (2)
| Title |
|---|
| ANURADHA KRISHNAMURTHY等: "Bispecific antibodies for cancer therapy: A review", PHARMACOL THER, 18 December 2017 (2017-12-18), pages 122 - 134, XP085376489, DOI: 10.1016/j.pharmthera.2017.12.002 * |
| D J FLAVELL等: "Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone", INT J CANCER, vol. 62, no. 3, 28 July 1995 (1995-07-28), pages 337 - 344 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210269545A1 (en) | 2021-09-02 |
| US20260103536A1 (en) | 2026-04-16 |
| WO2021173844A1 (en) | 2021-09-02 |
| JP2023516195A (ja) | 2023-04-18 |
| JP7811176B2 (ja) | 2026-02-04 |
| AU2021226582A1 (en) | 2022-10-13 |
| US20220363774A2 (en) | 2022-11-17 |
| US11299551B2 (en) | 2022-04-12 |
| EP4110818A1 (en) | 2023-01-04 |
| US20220185906A1 (en) | 2022-06-16 |
| KR20220159989A (ko) | 2022-12-05 |
| JP2026086474A (ja) | 2026-05-26 |
| MX2022010549A (es) | 2022-11-16 |
| US20220185907A1 (en) | 2022-06-16 |
| US12509527B2 (en) | 2025-12-30 |
| US20220185908A1 (en) | 2022-06-16 |
| CA3173257A1 (en) | 2021-09-02 |
| IL295896A (en) | 2022-10-01 |
| US12540194B2 (en) | 2026-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7811176B2 (ja) | C19 c38二特異性抗体 | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| US20240352156A1 (en) | Antibodies targeting immunosuppressive b cells | |
| US20240392000A1 (en) | Methods of treating cancers associated with immunosuppressive b cells | |
| CN114907479B (zh) | 抗cd112r抗体及其用途 | |
| CN115698066A (zh) | 抗cd47抗体及其用途 | |
| WO2022012559A1 (zh) | 抗cldn-18.2抗体及其用途 | |
| WO2024088342A1 (en) | Antibodies against cd24 and uses thereof | |
| HK40089438B (en) | Anti-cldn-18.2 antibody and use thereof | |
| HK40089438A (zh) | 抗cldn-18.2抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |